Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Christofides EA, Puente O, Norwood P, Denham D, Maheshwari H, Lillestol M, Hart T, Nakhle S, Chadha A, Fitz-Patrick D, Sugimoto D, Soufer J, Young D, Warren M, Huffman D, Reed J, Bays H, Arora S, Rizzardi B, Tidman R, Rendell M, Johnson KA.
Christofides EA, et al. Among authors: norwood p.
Diabetes Obes Metab. 2024 Jun;26(6):2412-2421. doi: 10.1111/dom.15560. Epub 2024 Apr 1.
Diabetes Obes Metab. 2024.
PMID: 38558508
Clinical Trial.